Back to top
more

Takeda Pharmaceutical Co. (TAK)

(Real Time Quote from BATS)

$18.63 USD

18.63
2,392,735

+0.34 (1.86%)

Updated Apr 8, 2026 03:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (94 out of 243)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Brokerage Reports

Research for TAK

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Takeda Pharmaceutical Co. [TAK]

Reports for Purchase

Showing records 1 - 20 ( 39 total )

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 1

03/20/2026

Industry Report

Pages: 72

Weekly Retail Sales Tracker for II in Derm/GI - Week Ended Mar. 13

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 2

03/13/2026

Industry Report

Pages: 114

Weekly Retail Sales Tracker for Solid Tumors - Week Ended March 6

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 3

03/06/2026

Industry Report

Pages: 114

Weekly Retail Sales Tracker for Solid Tumors - Week Ended February 27

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 4

11/30/2025

Industry Report

Pages: 114

Weekly Retail Sales Tracker for Solid Tumors - Week Ended November 21

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 5

11/23/2025

Industry Report

Pages: 114

Weekly Retail Sales Tracker for Solid Tumors - Week Ended November 14

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 6

10/24/2025

Industry Report

Pages: 114

Weekly Retail Sales Tracker for Solid Tumors - Week Ended October 17

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 7

10/03/2025

Industry Report

Pages: 114

Weekly Retail Sales Tracker for Solid Tumors - Week Ended September 26

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 8

09/26/2025

Industry Report

Pages: 114

Weekly Retail Sales Tracker for Solid Tumors - Week Ended September 19

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 9

09/19/2025

Industry Report

Pages: 114

Weekly Retail Sales Tracker for Solid Tumors - Week Ended September 12

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 10

07/11/2025

Industry Report

Pages: 115

Weekly Retail Sales Tracker for Solid Tumors - Week Ended July 4

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 11

07/06/2025

Industry Report

Pages: 115

Weekly Retail Sales Tracker for Solid Tumors - Week Ended June 27

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 12

06/27/2025

Industry Report

Pages: 115

Weekly Retail Sales Tracker for Solid Tumors - Week Ended June 20

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 13

06/06/2025

Industry Report

Pages: 114

Weekly Retail Sales Tracker for Solid Tumors - Week Ended May 30

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 14

05/16/2025

Industry Report

Pages: 113

Weekly Retail Sales Tracker for Solid Tumors - Week Ended May 9

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 15

05/09/2025

Industry Report

Pages: 113

Weekly Retail Sales Tracker for Solid Tumors - Week Ended May 2

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 16

05/02/2025

Industry Report

Pages: 113

Weekly Retail Sales Tracker for Solid Tumors - Week Ended April 25

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 17

04/11/2025

Industry Report

Pages: 113

Weekly Retail Sales Tracker for Solid Tumors - Week Ended April 4

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 18

04/04/2025

Industry Report

Pages: 113

Weekly Retail Sales Tracker for Solid Tumors

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 19

02/14/2025

Industry Report

Pages: 113

Weekly Retail Sales Tracker for Solid Tumors - Week Ended February 7

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party

Company: Takeda Pharmaceutical Co.

Industry: Medical - Drugs

Record: 20

02/07/2025

Industry Report

Pages: 113

Weekly Retail Sales Tracker for Solid Tumors - Week Ended January 31

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 150.00

Research Provided by a Third Party